Vertex Pharmaceuticals (VRTX) Net Income towards Common Stockholders (2016 - 2026)
Quarterly Net Income towards Common Stockholders rose 59.59% to $1.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.3 billion through Mar 2026, up 538.7% year-over-year, with the annual reading at $4.0 billion for FY2025, 838.09% up from the prior year.
Vertex Pharmaceuticals' Net Income towards Common Stockholders history spans 18 years, with the latest figure at $1.0 billion for Q1 2026.
- Net Income towards Common Stockholders came in at $1.0 billion for Q1 2026, down from $1.2 billion in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $1.2 billion in Q4 2025 to a low of -$3.6 billion in Q2 2024.
- The 5-year median for Net Income towards Common Stockholders is $930.5 million (2022), against an average of $670.0 million.
- Year-over-year, Net Income towards Common Stockholders soared 1109.7% in 2022 and then plummeted 492.44% in 2024.
- Vertex Pharmaceuticals' Net Income towards Common Stockholders stood at $818.9 million in 2022, then grew by 18.31% to $968.8 million in 2023, then dropped by 5.76% to $913.0 million in 2024, then soared by 30.46% to $1.2 billion in 2025, then dropped by 13.41% to $1.0 billion in 2026.
- Per Business Quant, the three most recent readings for VRTX's Net Income towards Common Stockholders are $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.63 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 30.42 Bn | 30.42 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.19 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 646.30 Mn |
| Dec 31, 2024 | 913.00 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | -3.59 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 968.80 Mn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 915.70 Mn |
| Mar 31, 2023 | 699.80 Mn |
| Dec 31, 2022 | 818.90 Mn |
| Sep 30, 2022 | 930.50 Mn |
| Jun 30, 2022 | 810.50 Mn |
| Mar 31, 2022 | 762.10 Mn |
| Dec 31, 2021 | 770.10 Mn |
| Sep 30, 2021 | 851.90 Mn |
| Jun 30, 2021 | 67.00 Mn |
| Mar 31, 2021 | 653.10 Mn |
| Dec 31, 2020 | 604.19 Mn |
| Sep 30, 2020 | 667.43 Mn |
| Jun 30, 2020 | 837.27 Mn |
| Mar 31, 2020 | 602.75 Mn |
| Dec 31, 2019 | 583.23 Mn |
| Sep 30, 2019 | 57.52 Mn |
| Jun 30, 2019 | 267.43 Mn |
| Mar 31, 2019 | 268.63 Mn |
| Dec 31, 2018 | 1.53 Bn |
| Sep 30, 2018 | 100.09 Mn |
| Jun 30, 2018 | 177.60 Mn |
| Mar 31, 2018 | 197.54 Mn |
| Dec 31, 2017 | 88.46 Mn |
| Sep 30, 2017 | -303.14 Mn |
| Jun 30, 2017 | -164.79 Mn |
| Mar 31, 2017 | 66.76 Mn |
| Dec 31, 2016 | -153.85 Mn |
| Sep 30, 2016 | -226.33 Mn |
| Jun 30, 2016 | -223.64 Mn |